Sarepta Therapeutics

YTD

ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

CEO

Douglas S. Ingram

CEODouglas S. Ingram

Employees

1,372

Employees1,372

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1980

Founded1980

Employees

1,372

Employees1,372

SRPT Key Statistics

Market cap

2.06B

Market cap2.06B

Price-Earnings ratio

-6.82

Price-Earnings ratio-6.82

Dividend yield

—

Dividend yield—

Average volume

3.03M

Average volume3.03M

High today

$20.93

High today$20.93

Low today

$19.65

Low today$19.65

Open price

$20.30

Open price$20.30

Volume

2.40M

Volume2.40M

52 Week high

$120.05

52 Week high$120.05

52 Week low

$10.42

52 Week low$10.42

Stock Snapshot

Sarepta Therapeutics(SRPT) stock is priced at $19.97, giving the company a market capitalization of 2.06B. It carries a P/E multiple of -6.82.

On 2026-02-05, Sarepta Therapeutics(SRPT) stock traded between a low of $19.65 and a high of $20.93. Shares are currently priced at $19.97, which is +1.6% above the low and -4.6% below the high.

Sarepta Therapeutics(SRPT) shares are trading with a volume of 2.4M, against a daily average of 3.03M.

During the past year, Sarepta Therapeutics(SRPT) stock moved between $10.42 at its lowest and $120.05 at its peak.

SRPT News

TipRanks 20h

Sarepta receives approval to start SRP-1005 trial in New Zealand

Sarepta (SRPT) Therapeutics announced that Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, has granted approval for its clinical trial...

Simply Wall St 1d

Assessing Sarepta Therapeutics Valuation After Positive Three Year EMBARK Data For Elevidys

Advertisement EMBARK data and what it means for Sarepta shares Sarepta Therapeutics (SRPT) recently reported positive three year functional results from its P...

Nasdaq 6d

Commit To Purchase Sarepta Therapeutics At $15, Earn 22.2% Annualized Using Options

Investors considering a purchase of Sarepta Therapeutics Inc (Symbol: SRPT) stock, but tentative about paying the going market price of $20.40/share, might bene...

Analyst ratings

54%

of 26 ratings

Buy

26.9%

Hold

53.8%

Sell

19.2%

More SRPT News

Simply Wall St 7d

How Sarepta’s Long-Term ELEVIDYS Duchenne Data At Sarepta Therapeutics Has Changed Its Investment Story

Earlier this week, Sarepta Therapeutics reported three-year topline results from its Phase 3 EMBARK trial showing ELEVIDYS produced statistically significant, d...

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.